Ception Therapeutics has rounded up $63 million in its third round of venture capital, with Essex Woodlands Health Ventures leading the way. Ception, which is based in Malvern Hill, PA, says that much of that money will be used to advance a late-stage biologic compound in clinical development for multiple inflammatory conditions, a small molecule anti-TNF program and other discovery programs. Investor Growth Capital, MDS Life Sciences Technology Fund II, New Science Ventures and Aperture Venture Partners all participated as investors.
- here's the release on the round
ALSO: Canada's Osprey Pharmaceuticals has garnered $9 million in financing, including $3 million in venture debt. Much of that is earmarked for early clinical trials of its lead product candidate, OPL-CCL2-LPM, for patients with chronic kidney disease. Release
PLUS: Abingworth has announced the closing of its $587 million life sciences fund, Abingworth Bioventures V. Company officials say the fund is the largest ever raised in Europe for the life sciences field. Release